Veru to Present Company Update at HC Wainwright BioConnect Conference January 10-13, 2022
MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) – Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company focused on the development of new drugs for the management of breast and prostate cancer, announced today hui that the Company will present at the HC Wainwright BioConnect conference. The presentation will be available via the Conference from January 10 to 13, 2022, starting at 7:00 a.m. Eastern Standard Time on January 10.
A webcast of the presentation will be available at https://verupharma.com/investors. Listeners are encouraged to visit the website at least 10 minutes before the start of the scheduled presentation to register, download and install any necessary software. The webcast will be archived and accessible on the website for at least 30 days.
About Veru Inc.
Veru is an oncology biopharmaceutical company primarily focused on the development of new drugs for the management of breast and prostate cancer.
The Company’s late stage breast cancer development portfolio includes enobosarm, a selective androgen receptor targeting agonist, and sabizabulin, a cytoskeletal disruptor.
Current studies on both drugs include:
Enobosarm ARTEST phase 3 enrollment in metastatic breast cancer with 40% AR (third-line metastatic receptor)
The Company has determined that patients who have ≥ 40% staining of androgen receptor nuclei by immunohistochemistry in their breast cancer tissue, a measure of RA expression, are the most likely to respond to enobosarm. Therefore, Veru is developing a companion diagnostic to determine a patient’s androgen receptor expression status. We have partnered with Roche / Ventana Diagnostics, a global leader in companion oncology diagnostics, who will develop and, if approved, commercialize AR companion diagnostics.
Veru’s advanced prostate cancer portfolio includes sabizabulin, VERU-100, a long-acting GnRH antagonist, and zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist.
Current studies on these drugs include:
Additionally, sabizabulin, which has a dual antiviral and anti-inflammatory effect, is currently in a Phase 3 study for the treatment of COVID-19 hospital patients at high risk of acute respiratory distress syndrome, also known as name of cytokine storm.
Veru also has a commercial sexual health division, the proceeds of which help fund our drug development programs. Its two main products are:
Statements contained in this press release that are not historical facts are “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this press release include statements regarding: timing where the commercial launch of ENTADFI will take place; the magnitude of the potential income generated by ENTADFI; whether the results of the Company’s current or future clinical development program will demonstrate sufficient efficacy and safety and potential benefits to secure FDA approval of the Company’s drug candidates; and whether the companion diagnostic for enobosarm will be successfully developed or be approved by the FDA for use. These forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unforeseen developments and risks related to: the development of the Company’s product portfolio and the results of clinical trials that may be unsuccessful or insufficient to meet applicable regulatory standards or justify continued development; the ability to enroll a sufficient number of subjects in clinical trials and the ability to enroll subjects according to scheduled schedules; the ability to fund planned clinical development; the timing of any submission to the FDA and any decisions made by the FDA or any other regulatory authority; the possibility that as vaccines become widely distributed, the need for new candidates for COVID-19 treatment may be reduced or eliminated; government entities possibly taking measures which, directly or indirectly, have the effect of limiting the opportunities for sabizabulin as a COVID-19 treatment, in particular by promoting other treatment alternatives or by imposing price controls on treatments COVID-19; the Company’s existing products and any future products, if approved, may not be commercially successful; the effects of the COVID-19 pandemic and measures to address it on clinical trials, the supply chain and other third-party vendors, business efforts and the Company’s business development operations; the Company’s ability to obtain sufficient financing on acceptable terms when necessary to finance development and operations; demand, market acceptance and competition for any product or product candidate of the Company; new or existing competitors with greater resources and capabilities and new approvals and / or introductions of competing products; changes in regulatory practices or policies or government-led healthcare reform efforts, including pricing pressures and changes in insurance coverage and reimbursement; the Company’s ability to successfully market any of its products, if approved; the Company’s ability to protect and enforce its intellectual property; the potential that delays in orders or shipments in connection with government tenders or the Company’s prescription activities in the United States could cause significant quarter-over-quarter variations in results of operation of the Company and adversely affect its net income and gross margin; the Company’s dependence on its international partners and on the level of spending by country governments, global donors and other public health organizations in the global public sector; the concentration of accounts receivable with our largest customers and the collection of those accounts receivable; the Company’s production capacity, efficiency and supply constraints and interruptions, including the potential interruption of production at the Company’s and third-party manufacturing facilities and / or the Company’s ability to deliver the product in a timely manner due to labor disputes or strikes, labor shortages, raw material shortages, physical damage to Company and third party facilities, COVID-19 (including impact of COVID-19 on key raw material suppliers), product testing, transportation delays or regulatory actions; costs and other effects of litigation, including product liability claims; the Company’s ability to identify, successfully negotiate and complete appropriate acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed from time to time in Company press releases, communications to shareholders and documents filed with the Securities and Exchange Commission, including the Company’s Form 10-K for the year ended September 30, 2021 and subsequent quarterly reports on Form 10-Q. These documents are available in the “SEC Filings” section of our website at www.verupharma.com/investors. The Company disclaims any intention or obligation to update these forward-looking statements.
Investor and media contact:
Executive Director, Investor Relations
and corporate communication
Email: [email protected]